We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic (MDT) Carpediem to Tap Pediatric Kidney Care Market
Read MoreHide Full Article
Medtronic plc (MDT - Free Report) recently made the commercial launch of its cardio-renal pediatric dialysis emergency machine, Carpediem. In April, the FDA granted marketing authorization for this device targeted to provide continuous hemodialysis or hemofiltration therapy to critically ill pediatric patients weighing between 2.5 and 10 kilograms or 5.5 to 22 pounds.
At Cincinnati Children's Hospital Medical Center, the first Carpediem system has been successfully installed.
Carpediem System at a Glance
The continuous hemodialysis or hemofiltration therapy is also known as continuous renal replacement therapy (CRRT). This system, implemented in ICU settings, uses dialysis machine and a special filter called dialyzer to clean a patient’s blood for an extended period of time, without any halt. This compares with the traditional three times a week therapy session.
Carpediem CRRT system is the first device for a lower weight-specific pediatric patient population. This system targets critically ill patients with high risk of acute kidney injury and fluid overload requiring hemodialysis or hemofiltration therapy.
Kidney Care Prospect in the Pediatric Market
At present, there are lucrative opportunities in pediatric dialysis market. Approximately 10,000 children develop acute kidney injury in the United States each year. According to Medtronic, children on its therapy have a survival rate of only 38-43%. The mortality rate for neonates with acute kidney injury has been reported to be as high as 60%.
Carpediem – a Strategic Inclusion
The existing CRRT devices available in the United States are intended for use in patients weighing at least 20 kilograms and are not approved for use in pediatric patients weighing between 2.5 and 10 kilograms. The CARPEDIEM System accordingly is expected to successfully address the untapped market of pediatric patients between 2.5 and 10 kilograms.
Price Performance
Over the past six months, Medtronic has outperformed the industry it belongs to. The stock has risen 14% compared with the industry's 8% rise.
Zacks Rank & Key Picks
Currently, Medtronic carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Hologic, Inc. (HOLX - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and ResMed Inc. (RMD - Free Report) .
Thermo Fisher’s long-term earnings growth rate is estimated at 18%. It currently carries a Zacks Rank #2 (Buy).
ResMed’s long-term earnings growth rate is estimated at 14.5%. The company presently carries a Zacks Rank #2.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don’t buy now, you may kick yourself in 2021.
Image: Bigstock
Medtronic (MDT) Carpediem to Tap Pediatric Kidney Care Market
Medtronic plc (MDT - Free Report) recently made the commercial launch of its cardio-renal pediatric dialysis emergency machine, Carpediem. In April, the FDA granted marketing authorization for this device targeted to provide continuous hemodialysis or hemofiltration therapy to critically ill pediatric patients weighing between 2.5 and 10 kilograms or 5.5 to 22 pounds.
At Cincinnati Children's Hospital Medical Center, the first Carpediem system has been successfully installed.
Carpediem System at a Glance
The continuous hemodialysis or hemofiltration therapy is also known as continuous renal replacement therapy (CRRT). This system, implemented in ICU settings, uses dialysis machine and a special filter called dialyzer to clean a patient’s blood for an extended period of time, without any halt. This compares with the traditional three times a week therapy session.
Carpediem CRRT system is the first device for a lower weight-specific pediatric patient population. This system targets critically ill patients with high risk of acute kidney injury and fluid overload requiring hemodialysis or hemofiltration therapy.
Kidney Care Prospect in the Pediatric Market
At present, there are lucrative opportunities in pediatric dialysis market. Approximately 10,000 children develop acute kidney injury in the United States each year. According to Medtronic, children on its therapy have a survival rate of only 38-43%. The mortality rate for neonates with acute kidney injury has been reported to be as high as 60%.
Carpediem – a Strategic Inclusion
The existing CRRT devices available in the United States are intended for use in patients weighing at least 20 kilograms and are not approved for use in pediatric patients weighing between 2.5 and 10 kilograms. The CARPEDIEM System accordingly is expected to successfully address the untapped market of pediatric patients between 2.5 and 10 kilograms.
Price Performance
Over the past six months, Medtronic has outperformed the industry it belongs to. The stock has risen 14% compared with the industry's 8% rise.
Zacks Rank & Key Picks
Currently, Medtronic carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Hologic, Inc. (HOLX - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) and ResMed Inc. (RMD - Free Report) .
Hologic’s long-term earnings growth rate is estimated at 17.4%. The company presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher’s long-term earnings growth rate is estimated at 18%. It currently carries a Zacks Rank #2 (Buy).
ResMed’s long-term earnings growth rate is estimated at 14.5%. The company presently carries a Zacks Rank #2.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don’t buy now, you may kick yourself in 2021.
Click here for the 6 trades >>